GSK (GSK) CEO Emma Walmsley stated that the company’s involvement in the FDA’s effort to update the prescribing information for leucovorin is purely administrative, emphasizing that GSK has no commercial or scientific interest in the decades-old drug, STAT’s Elaine Chen reports. Approved in 1983 and discontinued by GSK in 1997, leucovorin is now generic, and the FDA’s request to update its label for cerebral folate deficiency aims to enable generic manufacturers to reflect the new indication, Walmsley said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s RSV Vaccine Study Update: Promising Developments for Older Adults
- GSK’s NASH Study Completion: A Potential Game-Changer for Liver Disease Treatment
- GSK Advances Hepatitis B Treatment with Promising Study Update
- GSK’s Shingrix approved in China for prevention of shingles
- Trump Weekly: Generics to be excluded from pharma tariff plan